Bcr-Abl tyrosine kinase inhibitors (TKI) 
Introduction
The Philadelphia (Ph) chromosome and the resulting BCR-ABL fusion gene represent the pathogenetic hallmark of chronic myelogenous leukemia (CML). The deregulated tyrosine kinase activity of the Bcr-Abl protein alters cellular homeostatic mechanisms in primitive hematopoietic cells, resulting in increased proliferation, decreased apoptosis, and disturbed interaction with the extracellular matrix. The natural course of CML is an inevitable progression from an initial chronic phase (CP) to an accelerated phase (AP) and a fatal blast crisis (BC). Treatment with Imatinib mesylate (Imatinib), results in remarkably improved outcomes for CML patients. The majority of CP CML patients receiving Imatinib achieves and maintains major cytogenetic responses and substantial molecular responses (1, 2) . However, it is also known that primitive CML hematopoietic cells escape elimination by Imatinib and that discontinuation of drug results in disease relapse (3) . Previous studies suggest that effective inhibition of Bcr-Abl kinase activity by different tyrosine kinase inhibitor (TKI) is not sufficient to induce apoptosis in CML progenitors (4) (5) (6) (7) . These results indicate the importance of identifying the intracellular signaling mechanisms that are responsible for retention of CML progenitors despite Bcr-Abl kinase inhibition, and that could be targeted to enhance elimination of CML progenitor cells.
The Src family of nonreceptor tyrosine kinases have been identified as potential mediators of Bcr-Abl-induced leukemogenesis (8) (9) (10) . Overexpression of Src family kinases has been implicated in Imatinib resistance and CML progression (11) (12) (13) . Imatinib does not inhibit Src activity in mouse leukemic cells, suggesting that Src activation may also occur independently of BcrAbl kinase activity (14) (15) (16) . Dasatinib (BMS-354825), a highly potent dual Abl/Src kinase inhibitor, which is active against most Imatinibresistant mutants, has been approved for clinical use in CML patients who fail Imatinib (17) (18) (19) . Dasatinib inhibits wild-type BcrAbl and all members of the Src family, with an IC 50 of <1 nmol/L (20, 21) . However, it is not clear from previous studies whether Src kinase activity is elevated in primary progenitors from CML patients. In addition, the effects of Dasatinib on Src kinase activity in primary CML progenitor cells and on downstream signaling activities and apoptosis-regulating mechanisms have not been studied. In this study, we evaluated Src activity in primitive human CML progenitors from different stages of disease and investigated the effects of Dasatinib on Bcr-Abl and Src kinase activity and downstream growth signaling pathways in CP CML progenitors.
Patients, Materials, and Methods

Subjects
Peripheral blood samples were obtained from newly diagnosed CML patients. Peripheral blood stem cell (PBSC) and umbilical cord blood samples were obtained from healthy donors. This study was approved by the Institutional Review Boards at City of Hope Cancer Center, in accordance with an assurance filed with and approved by the Department of Health and Human Services, and the North Glasgow University Hospital Division of NHS Greater Glasgow and Clyde, and met all requirements of the Declaration of Helsinki.
Inhibitors
Ten-micromole per liter stock solutions of Dasatinib (Bristol-Myers Squibb) and Imatinib (Novartis Pharmaceuticals) were prepared in DMSO and stored at À20jC. Dasatinib was added to cell cultures at concentrations ranging between 0.01 and 0.15 Amol/L, and Imatinib was added at a concentration of 5 Amol/L, corresponding to plasma concentrations in patients receiving these agents (18, 22) .
Selection of CD34 + Progenitors
Mononuclear cells were isolated by Ficoll-Hypaque (Sigma Diagnostics) density gradient centrifugation (specific gravity, 1.077) for 30 min at 400 g. CD34 + cells were selected by means of immunomagnetic column separation (Miltenyi Biotech) following the manufacturer's instructions.
Cell Culture and Exposure to Inhibitors
+ cells were cultured with or without addition of Dasatinib or Imatinib at the indicated concentrations at 37jC in a humidified atmosphere with 5% CO 2 in serum-free medium (SFEM; StemCell Technologies) supplemented with growth factors (GF) at concentrations similar to that found in stroma-conditioned medium from longterm bone marrow cultures [LTBMC; 200 pg/mL granulocyte-macrophage colony-stimulating factor (CSF); 1 ng/mL G-CSF; 200 pg/mL stem cell factor; 50 pg/mL leukemia inhibitory factor; 200 pg/mL macrophageinflammatory protein-1a; and 1 ng/mL interleukin 6]. Cells were harvested after 96 h and assayed in progenitor, proliferation, and apoptosis assays.
Progenitor Assays
Colony-forming cells. To assess committed progenitors, CD34 + cells were plated in methylcellulose progenitor culture, and burst forming uniterythroid and colony-forming unit-granulocyte and macrophage were counted after 14 d.
Long-term culture-initiating cells. To assess primitive progenitors, CD34+ cells were plated in LTBMC medium on M2-10B4 murine fibroblast feeders subcultured in 96-well plates. Cultures were maintained at 37jC in a humidified atmosphere with 5% CO 2 and fed at weekly intervals. After 6 wk, wells were overlaid with colony forming cells (CFC) growth-supporting medium and scored as positive or negative for the presence of CFC after 2 wk. The frequency of long-term culture-initiating cells (LTC-IC) was calculated with L-Calc software (StemCell Technologies). Results from the CFC and LTC-IC were reported as percentage of growth inhibition versus control.
Flow Cytometry
CD34
+ CD38 + and CD34 + CD38 À progenitor cells were labeled with 5-(and 6-) carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes) as described previously (7). CFSE-labeled cells were cultured for 96 h in the presence or absence of inhibitors. At the end of the culture period, cells were labeled with Annexin V-PE (BD Pharmingen). Cell division was analyzed on the basis of CFSE fluorescence measured by flow cytometry (FACScalibur; Becton Dickinson). The percentage of cells in different generations was enumerated and a proliferation index was generated using ModFit software (Verity). Apoptotic cells were defined as Annexin V-PE + . Intracellular phospho-Src (P-Src Alexa-Fluor 488; Upstate) and phospho-Crk-like (P-CrkL; Cell Signalling) staining were performed and analyzed by flow cytometry using methods described previously (14) .
Western Blot Analysis
CD34
+ cells were cultured in medium containing low concentrations of GFs, with or without inhibitors, for 16 h. Cells were lysed in buffer containing 0.5% Nonidet P-40 (Sigma Diagnostics) and 0.5% sodium deoxycholate supplemented with phenylmethylsulfonyl fluoride (1 mmol/L), protease inhibitor mixture, and phosphatase inhibitors (50 mmol/L Sodium Fluoride, 1 mmol/L Sodium Vanadate; all from Sigma Diagnostics). Proteins were resolved on 10% SDS-PAGE gels and transferred to nitrocellulose membrane. Membranes were sequentially reprobed with primary and secondary antibodies. Primary antibodies used were as follows: anti-CrkL rabbit polyclonal antibody (sc-319), anti-Phosphotyrosine mouse monoclonal antibody (mAb; 4G10; Millipore) anti-phosphorylated p42/44 mitogenactivated protein kinase (P-MAPK) mouse mAb (sc-7383), anti-p42/44 MAPK rabbit polyclonal antibody (sc-94), anti-STAT5 rabbit polyclonal antibody (sc-835), anti-Bcl-2 (100) mouse mAb (sc-509), anti-Mcl-1 (S-19) rabbit polyclonal antibody (sc-819; all from Santa Cruz Biotechnology), antiphosphorylated STAT5 (P-STAT5; Tyr694) rabbit polyclonal antibody, antiphosphorylated Akt (P-Akt; Ser473) rabbit polyclonal antibody, anti-Akt rabbit polyclonal antibody, anti-phosphorylated Src Family (Tyr416) rabbit polyclonal antibody and anti-Src rabbit polyclonal antibody (all from Cell Signaling Technology), anti-actin mouse mAb (clone AC-15), anti-Bim (BOD) rabbit polyclonal antibody (all from Sigma), and anti-Bcl-X L rabbit polyclonal antibody (BD Biosciences). Horseradish peroxidase-or alkaline phosphatase-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories. Antibody detection was performed using the Superfemto kit (Pierce Biotechnology). The protein expression levels were determined by densitometry using Image-Quant software (Amersham Pharmacia Biotech).
Fluorescent In situ Hybridization Analysis
Fluorescence in situ hybridization (FISH) analysis was performed as previously described (23) . Colonies from CFC assays were harvested, pooled, and washed. Cells were resuspended in hypotonic KCl solution, centrifuged, and fixed using Carnoy fixative. Hybridization using the LSI dual-labeled Bcr-Abl DNA probe was performed in accordance with the manufacturer's instructions (Vysis). Lymphocytes from a healthy individual served as a BcrAbl negative control; SD-1 cell lines, derived from an acute lymphoblastic leukemia (ALL) patient, served as a Bcr-Abl positive control. A total of 200 nuclei were scored for each sample.
Statistical Analysis
Data obtained from independent experiments were reported as the mean F SE. Student's t test analysis was performed to determine statistical significance.
Results
Src phosphorylation is enhanced in primitive and committed progenitor cells from CML patients. P-Src expression was assessed in CD34 + and more primitive CD34 There was again a trend toward higher P-Src levels in the BC compared with CP samples. There was also a trend toward higher P-Src levels in total CD34+ cells compared with CD34+CD38À cells (Fig. 1D ). These results indicate that P-Src expression is increased in CD34 + cells and CD34
+ CD38
À cells in all phases of CML.
Dasatinib effectively inhibits Src and Bcr-Abl kinase activity in CML primitive and committed progenitor cells. The effects of Dasatinib and Imatinib on Src and Bcr-Abl kinase activity were assessed after 16 hours of exposure in culture. On assessment by intracellular flow cytometry, Dasatinib significantly reduced P-Src expression in both CML CD34 + (P < 0.001) and more primitive CML CD34 + CD38
À cells (P < 0.001) compared with no drug controls ( Fig. 2A) . Imatinib also inhibited P-Src expression in CML CD34+ (P < 0.001) and CD34 + CD38 À cells (P = 0.003) but to a lesser extent than Dasatinib. We also assessed P-Src levels by performing Western blot analysis for P-Src on protein extracts from CD34 + cells treated with Dasatinib and Imatinib. As was seen with flow cytometry assays, Western blot analysis also indicated that P-Src levels were effectively suppressed in response to Dasatinib (0.01-0.15 Amol/L) treatment (P < 0.001; Fig. 2B ). P-Src levels were only partially suppressed after treatment with Imatinib (5 Amol/L; P = 0.06). To study the effect of Dasatinib on Bcr-Abl kinase activity, we performed Western blotting for P-CrkL, which can be distinguished from nonphosphorylated CrkL by its slower migration on Western blots. As shown in Fig. 2C , treatment with Dasatinib at doses as low as 0.01 Amol/L effectively suppressed P-CrkL protein levels (P < 0.001). Increasing the Dasatinib concentration to 0.15 Amol/L resulted in further suppression of P-CrkL levels. P-CrkL levels were also suppressed after treatment with 5 Amol/L Imatinib (P < 0.001). We also preformed Western blotting for phosphorylated Bcr-Abl and Abl (Fig. 2D ). Membranes were sequentially probed with anti-Phosphotyrosine and anti-Abl antibodies to detect phosphorylated and total Bcr-Abl. Potent inhibition of Bcr-Abl phosphorylation was observed, consistent with the results of anti-CrkL blotting.
Dasatinib inhibits MAPK, Akt, and STAT5 phosphorylation in CML progenitors in the absence of GFs, but phosphorylation is maintained in the presence of GFs. The MAPK, Akt, and STAT5 signaling pathways are activated downstream of Bcr-Abl and may contribute to abnormal proliferation and survival of CML progenitors. We assessed the activity of these signaling pathways in CML CD34+ cells after 16 hours of exposure to Imatinib (5 Amol/L) and Dasatinib (0.01-0.15 Amol/L) with or without exogenous GF. Consistent with our previous observations, treatment with Imatinib, in the presence of GF, resulted in increased MAPK activity in CML CD34 + cells (31.4-F 14.4-fold; n = 4). Increased MAPK activity was less prominent with Dasatinib treatment than with Imatinib treatment and was only seen at the highest concentrations of Dasatinib (7.6-F 4.0-fold at 0.15 Amol/L Dasatinib; Fig. 3A) . Incubation of CML CD34+ cells with Dasatinib in the presence of GF did not lead to a significant change in P-Akt and P-STAT levels in CML CD34+ cells (Fig. 3B and C) . Similar results were obtained with Imatinib.
GF receptor engagement may also contribute to signaling through the MAPK, phosphatidylinositol-3-OH kinase (PI-3K)/Akt and STAT5 pathways. Dasatinib exposure in the presence or absence of GF stimulation resulted in similar inhibition of P-CrkL. However, inhibition of P-Src in response to low levels of Dasatinib (0.01 Am) was enhanced in the absence of GF. Similarly, Imatinib effectively inhibited Src signaling in the absence of GF but resulted in partial inhibition of P-Src levels in the presence of GF. These results suggest a role for GF stimulation in residual Src signaling in cells exposed to low levels of Dasatinib and to Imatinib. Exposure to Dasatinib in the absence of GF resulted in complete inhibition of P-STAT5 and reduction in P-MAPK, P-Akt, and P-STAT5 levels (Fig. 4A) . Similar effects were seen with Imatinib. Because signaling in the absence of GF is likely to be mainly Bcr-Abl driven, these results suggest that Dasatinib effectively inhibits Bcr-Abl-mediated activation of the MAPK, PI-3K, and STAT5 pathways. In contrast, Results are expressed as a percentage of the no drug control (FSE). There was no difference between CP and BC CML in the samples assessed. The effect of inhibitors on P-Src, total Src, and Actin was also assessed by Western blotting (B). A representative blot for one CML sample is shown. Expression of P-Src (P-Src/actin ratio) after inhibitor treatment expressed as a percentage of P-Src expression in the absence of inhibitors is shown; columns, mean of three replicate experiments; bars, SE. Significant differences in protein expression levels for treated cells compared with untreated controls are indicated for Dasatinib (***, P < 0.001; **, P < 0.01). To assess the effect of Dasatinib or Imatinib on Bcr-Abl kinase activity, Western blotting was performed using anti-CrkL antibodies (C). Representative blots for one CML sample are shown. P-CrkL (P-CrkL/total CrkL ratio) expressed as percentage of P-CrkL in the absence of inhibitors is shown; columns, mean (n = 5); bars, SE. Significant differences in protein expression levels for treated cells compared with untreated controls are indicated for Imatinib ( +++ , P < 0.001) and Dasatinib ( *** the additional Src inhibition by Dasatinib does not further inhibit signaling through the MAPK, PI-3K, and STAT5 pathways in cells exposed to GF.
Dasatinib treatment does not alter apoptosis-regulating proteins and has only modest effects on CML progenitor cell apoptosis in the presence of GFs but has significant antiproliferative effects. CML, cord blood, and normal PBSC CD34+ cells were cultured for 96 hours in low GF conditions with or without Dasatanib or Imatinib, and the number of CFC (committed progenitors) and LTC-IC (primitive progenitors) present after culture was assessed. Dasatinib resulted in dose-dependent suppression of CML LTC-IC compared with untreated controls (P = 0.0008; Fig. 5A ). Dasatinib treatment also resulted in a significant, dose-dependent suppression of CML CFC (P = 0.0001; Fig. 5A ). Suppression of CML CFC and LTC-IC by Dasatinib was comparable with that observed with 5 Amol/L Imatinib treatment (P = 0.0002 and 0.001, respectively). We have shown that Imatinib shows higher potency of inhibition of CML CFC compared with LTC-IC (7). Results shown in Fig. 5A indicate that Dasatinib similarly inhibits CML CFC more effectively than LTC-IC at low concentrations (0.01 Amol/L). This is consistent with a greater effect of these inhibitors on committed compared with primitive progenitors. FISH analysis of colonies generated in CFC culture revealed that 98.3% F 0.4% (n = 4) of cells derived from CFC from untreated cells were BCR-ABL positive. CFC remaining after Dasatinib or Imatinib treatment were also predominantly BCR-ABL positive (0.15 Amol/L Dasatinib: 84.8% F 12.7%, n = 3; 5 Amol/L Imatinib: 94.8% F 4.3%, n = 4), indicating persistence of BCR-ABLpositive cells. Dasatinib treatment suppressed cord blood LTC-IC and CFC to a lesser extent than CML progenitors (Fig. 5B) . Dasatinib also inhibited normal PBSC CFC to a lesser extent than CML CFC (Fig. 5C) .
To assess the effects of Dasatinib on apoptosis, CML CD34 + 38 (Fig. 6A and B) . We also evaluated the effect of Dasatinib treatment on the expression of proteins known to be important in regulating apoptosis and reported to be regulated by Bcr-Abl, including the antiapoptotic proteins Mcl-1, Bcl-2, and Bcl-xL and the proapoptotic protein Bim. Treatment with Dasatinib in the presence of GF did not result in alteration in the expression of Mcl-1, Bcl-2, Bcl-X L , and Bim after adjusting for protein loading based on actin (Fig. 6C) . These results suggest that maintenance of signaling through the GF-receptors is sufficient to prevent alterations in these apoptosis regulatory mechanisms after Dasatinib treatment. Fig. S1A ). Dasatinib also inhibited proliferation of cord blood primitive progenitors ( Supplementary Fig. S1B ) and normal PBSC primitive and committed progenitors (Supplementary Fig. S1C ) but to a lesser extent than CML progenitors. An increased proportion of undivided progenitors were seen after Dasatinib treatment, as has been previously described for Imatinib ( Supplementary Fig S1D; refs. 14, 24). Annexin V labeling indicated that apoptosis was largely restricted to dividing cells and that nondividing CML progenitors were resistant to apoptosis after Dasatinib and Imatinib treatment (Fig. 6D) . + cells were incubated with Dasatinib or Imatinib for 16 h in low GF-containing medium as described in the Materials and Methods. Cell lysates were prepared and Western blotting was performed using anti-P-MAPK, anti-MAPK, and anti-actin antibodies. Representative blots for one CML sample are shown. Densitometry analysis was performed and the ratio of phosphorylated protein/actin was calculated. Columns, mean fold increase of phosphorylated protein compared with untreated control based on replicate experiments (n = 4; A ); bars, SE. Western blotting was performed using anti-P-Akt and anti-Akt (B), and anti-P-STAT5 and anti-STAT5 (C ), and anti-actin antibodies. The results shown are representative of n = 4 to 5 experiments using different CML patient samples.
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Discussion
Imatinib treatment has been shown to be highly effective in all phases of CML with most patients achieving substantial and prolonged reduction in levels of Bcr-Abl-positive cells. However, low levels of residual Bcr-Abl expressing stem and progenitor cells can be detected in most CML patients in remission on Imatinib (25) . Imatinib does not effectively induce apoptosis in primitive CML progenitors, despite inhibiting Bcr-Abl tyrosine kinase activity in these cells (5, 14) . The mechanisms that contribute to preservation of CML progenitors in patients receiving Bcr-Abl TKI treatment are unclear because previous studies indicate that Imatinib and other TKI can effectively inhibit Bcr-Abl kinase activity in CD34+ cells. Here, we evaluated Src kinase activity and the effect of blocking Src signaling with Dasatinib on primitive human CML progenitors.
Our studies show that human CML stem and progenitor cells display increased Src kinase activity. Although studies in myeloid cell lines have shown that Bcr-Abl can directly and indirectly Bcr-Abl and GF receptors both signal through the MAPK, PI-3K/Akt, and STAT5 pathways through Src-dependent and -independent mechanisms. In addition, BCR-ABL-transformed cells and primary CML progenitors show enhanced autocrine secretion of GF (dashed line ). Imatinib-mediated inhibition of Bcr-Abl kinase activity results in reduced downstream signaling through Src-dependent and Src-independent mechanisms in addition to inhibition of Bcr-Abl-mediated autocrine GF signaling. However, Src signaling through GF receptor engagement and other Bcr-Abl-independent mechanisms is not affected. Dasatinib in addition to inhibiting Bcr-Abl kinase-dependent signaling such as Imatinib also inhibits Bcr-Abl-independent Src signaling. Although the additional Src inhibition leads to reduced elevation of P-MAPK levels in response to exogenous GF, Src-independent GF-activated signals can persist in Dasatinib-treated cells.
Effects of Dasatinib on Signaling in CML Progenitors
www.aacrjournals.org interact with and activate Src family kinases (10), previous studies have not directly evaluated Src kinase expression and activity in primary CML cells. Other studies have shown that Bcr-Abl retrovirus-transduced marrow from mice lacking Src kinases efficiently induced CML but not B-ALL in transplant recipients, and Src kinase inhibitors prolonged survival of mice with B-ALL but not with CML (26) . These studies suggested an important role for Src in Ph+ALL, whereas its activity and role in CML is less clear. We show here that levels of P-Src are significantly increased in CD34+ and CD34+CD38À cells from patients with CP CML. Increased Src activity was associated with disease progression with a trend toward increased P-Src in cells from patients with BC compared with CP CML. Interestingly, P-Src levels were higher in CD34+ cells compared with CD34+CD38À cells, indicating maturation stage-related changes in Src activity. We further show that Imatinib treatment only partially inhibited P-Src levels in CML progenitors, whereas Dasatinib potently inhibited Src kinase activity under these conditions. These studies were conducted in cells exposed to exogenous GF. Because Src kinases can be activated by signaling from GF receptors, we also studied the effects of inhibitors in the absence of GF. Dasatinib and Imatinib were both highly effective in inhibiting Src signaling in the absence of GF, suggesting that incomplete inhibition of Src in CML cells exposed to exogenous GF may be related to GF receptor-mediated activation of Src. These results indicate that both Bcr-Abl and nonBcr-Abl kinase-dependent mechanisms contribute to Src activation in CML progenitor cells and that whereas Imatinib only inhibits Bcr-Abl kinase mediated Src activation, both Bcr-Abl kinase-dependent and kinase-independent Src activation are inhibited by Dasatinib. These observations help clarify the relationship of Bcr-Abl kinase Src activity in human CML progenitors.
Our studies elucidate the relative contribution of Src and Bcr-Abl kinases to the activity of important downstream signaling pathways in CML progenitors. Src kinases are known to play an important role in regulating mitotic events and, such as the BcrAbl kinase, can activate the STAT5, PI-3K/Akt, and MAPK signaling pathways (27, 28) . We show here that exposure to Dasatinib in the absence of GF resulted in almost complete suppression of P-STAT5 expression and reduced P-MAPK and P-Akt expression. However, Imatinib resulted in similar suppression of P-STAT, P-Akt, and P-MAPK, suggesting that combined inhibition of Src and Bcr-Abl kinase activity did not result in increased suppression of these signaling pathways. Although GF signaling from autocrine mechanisms has been observed in primitive CML cells even in the absence of exogenous GF (29) , autocrine GF production and signaling is Bcr-Abl kinase dependent and rapidly inhibited with Imatinib treatment (30) . On the other hand, treatment with Dasatinib in the presence of GF did not inhibit P-STAT5 or P-Akt expression in CML CD34 + cells. This indicates that inhibition of Src activity did not suppress GF-activated signaling through these pathways. In contrast, a dose-dependent increase in MAPK activity observed in CD34 + progenitor cells treated with Imatinib in the presence of GF was much less apparent after Dasatinib treatment, suggesting that Src signaling may contribute to increased MAPK activity under these conditions. Importantly, inhibition of Src signaling in combination with BcrAbl kinase inhibition by Dasatinib did not induce proapoptotic signals in CML progenitors. This is consistent with our previous and current observations that primitive CML CP cells are resistant to induction of apoptosis with Dasatinib (4, 14) . Primitive leukemic cells from mice with Bcr-Abl retrovirus-induced B-ALL and CML have also been shown to be insensitive to both Imatinib and Dasatinib treatment (31) . These observations suggest that combined Src and Bcr-Abl kinase inhibition does not enhance targeting of primitive progenitors from CP CML patients. It remains possible that Src inhibition may have a role in advanced phase or Imatinibresistant CML. Overexpression of Src family kinases has been implicated in Imatinib resistance and CML progression, and short interfering RNA targeting the Src kinase Lyn can induce apoptosis in CML BC cells (11, 13 ). An adaptive increase in GF production and Jak2 signaling may contribute to Imatinib resistance, and inhibition of Src signaling may also be beneficial in this context (28, 32) .
Dasatinib significantly suppressed CML primitive and committed progenitor cells in LTC-IC and CFC assays. Dasatinib also significantly reduced the number of dividing cells observed on CFSE tracking experiments. These observations, together with the lack of apoptosis in undivided cells, suggest that Dasatinib suppresses progenitor growth through inhibition of proliferation and a modest increase in apoptosis in dividing progenitors. These effects are very similar to those of Imatinib and again indicate that additional Src inhibition by Dasatinib did not enhance suppression and targeting of CML primitive and committed progenitors. The effects of Dasatinib treatment are similar to those obtained with another dual Bcr-Abl and Src inhibitor, SKI-606. Although less potent than Dasatinib, active concentrations of SKI-606 that effectively inhibit Bcr-Abl and Src kinase activity have similar effects on CML progenitor apoptosis, proliferation, and growth in CFC and LTC-IC assays, with relatively little effect on normal progenitors (6).
In conclusion, our results indicate that Src kinase activity is enhanced in CML progenitor cells and that Dasatinib, although highly effective in inhibiting Src and Bcr-Abl kinase activity in CML progenitor cells, does not show enhanced suppression of important downstream signaling mechanisms compared with Imatinib. The enhanced Src inhibiting activity of Dasatinib does not significantly alter apoptosis regulating proteins in CML progenitors. Although our results indicate that Imatinib and Dasatinib effectively inhibit BCR/ABL kinase activity in primitive CML cell populations, it is important to also consider that there may be considerable heterogeneity in BCR-ABL expression, drug uptake and efflux, and the presence of additional genetic abnormalities within the purified populations studied. Persistence of small populations of malignant stem and progenitor cells despite inhibitor treatment could allow accumulation of additional genetic aberrations leading to drug resistance or evolution to BC. Indeed, we have shown that BCR-ABL kinase mutations can be detected in CD34+ cells from CML patients in CCR on Imatinib, may contribute to persistence of small populations of malignant progenitors, and could be a potential source of relapse or progression (25) . Although we cannot exclude the possibility that Bcr-Abl and Src kinase activated is not inhibited in a small subset of CML cells that are not detectable using the assays used here, the lack of apoptosis in the bulk of CML progenitors after TKI treatment cannot be explained by lack of inhibition of Bcr-Abl and Src kinase activity. Therefore, the use of more potent Abl kinase inhibitors or dual Src-Abl kinase inhibitors may not by itself to enhance targeting of residual CML progenitors, and other pathways for CML stem and progenitor cell survival need to be identified and targeted to enhance their elimination. In this respect, our recent observations that farnesyl transferase inhibitors and histone deacetylase inhibitors (33, 34) are capable of effectively inducing apoptosis in quiescent CML primitive progenitors indicate promising areas for further investigation.
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